Edition:
United Kingdom

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

31.10SEK
23 Feb 2018
Change (% chg)

-1.65kr (-5.04%)
Prev Close
32.75kr
Open
32.80kr
Day's High
32.85kr
Day's Low
30.65kr
Volume
1,265,374
Avg. Vol
332,958
52-wk High
44.27kr
52-wk Low
24.31kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 0.71
Market Cap(Mil.): kr3,270.22
Shares Outstanding(Mil.): 82.17
Dividend: 0.28
Yield (%): 0.70

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln

* Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO

22 Feb 2018

BRIEF-Karo Pharma Says RORgamma Project Is Not Shut Down

* SAYS RORGAMMA PROJECT IS NOT SHUT DOWN BUT CARRIES ON AS PLANNED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Jan 2018

BRIEF-Karo Pharma Rights Issue Subscribed To 170 Percent

* RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

04 Jan 2018

BRIEF-Karo Pharma: New Issue To Provide Up To SEK 794.3 Ml‍n Before Issue Costs

* SAYS NEW ISSUE TO PROVIDE UP TO SEK 794.3 ML‍N BEFORE ISSUE COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Dec 2017

BRIEF-Karo Pharma Chairman Called For Inquiry For Inside Trading

* CHAIRMAN CALLED IN TO INQUIRY FROM POLICE FOR INSIDE TRADING

30 Nov 2017

BRIEF-Karo Pharma signs agreement with Marinomed Biotech

* KARO PHARMA ANNOUNCES AGREEMENT WITH THE AUSTRIAN PHARMACEUTICAL COMPANY MARINOMED BIOTECH AG

27 Nov 2017

BRIEF-Karo Pharma to carry out new issue

* TO CARRY OUT NEW ISSUE WITH PROCEEDS AT ABOUT SEK 800 MILLION BEFORE ISSUE COSTS IF FULLY SUBSCRIBED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Nov 2017

BRIEF-Karo Pharma Q3 EBITDA up at SEK ‍34.0​ mln

* Q3 NET SALES SEK ‍137.1​ MILLION VERSUS SEK 85.2 MILLION YEAR AGO

02 Nov 2017

BRIEF-Karo Pharma Q3 EBITDA sharply up yr/yr​

* Says ‍net sales amounted to MSEK 418.9 (250.8), whereof Q3 MSEK 137.1 (85.2)​

02 Nov 2017

BRIEF-Karo Pharma owns 97 pct in Weifa upon completion of voluntary offer

* ‍KARO PHARMA NOW HOLDS 97.21% OF SHARES AND VOTING RIGHTS IN WEIFA.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

06 Oct 2017

Earnings vs. Estimates

No consensus analysis data available.